Treatment of active tuberculosis: Challenges and prospects

Clinics in Chest Medicine

Volumn 26, Issue 2, 2005, Pages 273-282

  Sahbazian, Behzad ^a   Weis, Stephen E ^b  

^a JOHN PETER SMITH HOSPITAL   (United States)

^b University of North Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; BILIRUBIN; CAPREOMYCIN; CYCLOSERINE; DEXAMETHASONE; ETANERCEPT; ETHAMBUTOL; GATIFLOXACIN; INFLIXIMAB; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LIVER ENZYME; MOXIFLOXACIN; PYRAZINAMIDE; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ANOREXIA; ANTIBIOTIC THERAPY; ARTHRALGIA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BODY FLUID; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DROWSINESS; DRUG SAFETY; DRUG SENSITIVITY; DYSPEPSIA; ENZYME DEFECT; FAINTNESS; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; GOUT; HEADACHE; HEPATITIS; HUMAN; HYPOTENSION; IRRITABILITY; KIDNEY FAILURE; LACRIMAL FLUID; LEUKOPENIA; LIVER TOXICITY; MYALGIA; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RASH; RETROBULBAR OPTIC NEUROPATHY; REVIEW; SEIZURE; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TEAR DISCOLORATION; THROMBOCYTOPENIA; TREATMENT PLANNING; TUBERCULOSIS; TUBERCULOUS MENINGITIS; URINE; URINE DISCOLORATION; VISUAL IMPAIRMENT; WITHDRAWAL SYNDROME;

EID: 17044366978     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2005.02.011     Document Type: Review

References (65)

1. A. Vernon, W. Burman, and D. Benator Relapse with rifamycin mono-resistant tuberculosis in HIV-infected patients treated with supervised once-weekly rifapentine and isoniazid Lancet 353 1999 1843 1847
2. Centers for Disease Control and Prevention Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens MMWR Morb Mortal Wkly Rep 51 2002 214 215
3. D. Benator, M. Bhattacharya, and L. Bozeman Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial Lancet 360 2002 528 534
4. M. Weiner, W. Burman, and A. Vernon Tuberculosis Trials Consortium. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine Am J Respir Crit Care Med 167 2003 1341 1347
5. M. Weiner, N. Bock, and C.A. Peloquin Tuberculosis Trials Consortium. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy Am J Respir Crit Care Med 169 2004 1191 1197
6. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America Treatment of tuberculosis MMWR Recomm Rep 52 RR-11 2003 1 77
7. Medical Research Council Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic Acid BMJ 2 1950 1073 1085
8. W. McDermott, C. Mushenheim, and S.J. Hadley Streptomycin in the treatment of tuberculosis in humans Ann Intern Med 27 1947 769 822
9. C.W. Tempel, F.J. Hughes, and R.E. Mardis Combined intermittent regimes employing streptomycin and para-aminosalicycylic acid in the treatment of pulmonary tuberculosis Am Rev Tuberc 63 1951 295 311
10. G. Canetti, and J. Grosset Teneur des souches sauvages de mycobacterium tuberculosis en variants resistants a l'isoniazide et en variants resistants a la streptomycine sur milieu de Lowenstein-Jensen Ann Inst Pasteur (Paris) 101 1961 28
11. G. Canetti, N. Rist, and J. Grosset Primary drug resistance in tuberculosis Am Rev Resp Dis 90 1964 792 799
12. H.L. David Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis Appl Microbiol 20 1970 810 814
13. H.L. David Drug-resistance in M. Tuberculosis and other mycobacteria Clin Chest Med 1 1980 227 230
14. D.A. Enarson Resistance to antituberculosis medication. Hard lessons to learn Arch Intern Med 160 2000 581 582
15. W. Fox Changing concepts in the chemotherapy of pulmonary tuberculosis Am Rev Resp Dis 97 1968 767 790
16. C.A. Peloquin Tuberculosis drug serum levels Clinical Infectious Diseases 33 2001 584 585
17. C.A. Peloquin Therapeutic drug monitoring in the treatment of tuberculosis Drugs 62 2002 2169 2183
18. H. Bang, L. Kramer Jacobsen, and E. Strandgaard Metabolism of isoniazid and para-amino-salicylate acid (PAS) in the organism and its therapeutic significance Acta Tuberc Scand 41 1962 237 251
19. J.R. Mitchell, W.J. Zimmerman, and F.G. Ishak isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis Ann Intern Med 84 1976 181 192
20. W.W. Weber, and D.W. Hein Clinical pharmacokinetics of isoniazid Clin Pharmacokinet 4 1979 401 422
21. C.M. Nolan, S.V. Goldberg, and S.E. Buskin Hepatotoxicity associated with isoniazid preventive therapy JAMA 281 1999 1014 1018
22. M.A. Steele, R.F. Burk, and R.M. DesPrez Toxic hepatitis with isoniazid and rifampin Chest 99 1991 465 471
23. D.E. Kopanoff, D.E. Snider, and G.J. Caras Isoniazid related hepatitis: a US Public Health Service cooperative surveillance study Am Rev Respir Dis 117 1979 991 1001
24. S. Salpeter Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis West J Med 159 1993 560 564
25. D.E. Snider, and G.J. Caras Isoniazid-associated hepatitis deaths: a review of available information Am Rev Respir Dis 145 1992 494 497
26. T.G. Rothfield, W.F. Bierer, and J.W. Garfield Isoniazid induction of antinuclear antibodies Ann Intern Med 88 1978 650 652
27. D. Yee, C. Valiquette, and M. Pelletier Incidence of serious side effects from first line anti-tuberculosis drugs among patients treated for active tuberculosis Am J Respir Crit Care Med 167 2003 1472 1477
28. J.M. Dickinson, and D.A. Mitchinson Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis Am Rev Respir Dis 123 1981 367 371
29. D.J. Girling Adverse reactions to rifampicin in antituberculous regimens J Antimicrob Chemother 3 1977 115 132
30. M.A. Steele, R.F. Burk, and R.M. DesPrez Toxic hepatitis with isoniazid and rifampin Chest 99 1991 465 471
31. E. Martinez, J. Collazos, and J. Mayo Hypersensitivity reactions to rifampin Medicine 78 1999 361 369
32. J. Grosset, and S. Leventis Adverse affects of rifampin Rev Infect Dis 5 1983 S440 S450
33. D.E. Griffith, B.A. Brown, and R.J. Wallace Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease Clin Infect Dis 23 1996 1321 1322
34. M.A. Blajchman, R.C. Lowry, and J.E. Pettit Rifampicin-induced immune thrombocytopenia BMJ 3 713 1970 24 26
35. B. Doster, F.J. Murray, and R. Newman Ethambutol in the initial treatment of pulmonary tuberculosis Am Rev Respir Dis 107 1973 177 190
36. J.E. Leibold The ocular toxicity of ethambutol and its relation to dose Ann N Y Acad Sci 135 1966 904 909
37. S.H. Gillespie, and N. Kennedy Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 2 1998 265 271
38. P. Ball, and G. Tillotson Tolerability of fluoroquinolone antibiotics. Past, present and future. Infectious Diseases Unit, Victoria Hospital, Kirkcaldy, Fife, Scotland Drug Saf 13 6 1995 343 358
39. D.A. Mitchison Understanding the chemotherapy of tuberculosis-current problems J Antimicrob Chemother 29 1992 477 493
40. N. Solomon, D.C. Perlman, and S. Goldstein Special problems in treating tuberculosis [letter] An Intern Med 120 1994 400 401
41. D.N. Fish, and A.T. Chow The clinical pharmacokinetics of levofloxacin Clin Pharmacokinet 32 1997 101 119
42. B.A. Lipsky, and C.A. Baker Fluoroquinolone toxicity profiles: a review focusing on newer agents Clin Infect Dis 28 1999 352 364
43. D.J. Girling The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis Tubercle 65 1984 1 4
44. G.A. Ellard Absorption, metabolism, and excretion of pyrazinamide in man Tubercle 50 1969 144 158
45. P.J. Jenner, G.A. Ellard, and W.G. Allan Serum uric concentrations and arthralgias among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore Tubercle 62 1981 175 179
46. R.D. Meyer Amikacin Ann Intern Med 95 1981 328 332
47. S.M. Finegold Kanamycin Arch Intern Med 104 1981 15 18
48. B.W. Allen, D.A. Mitchison, and Y.C. Chan Amikacin in the treatment of pulmonary tuberculosis Tubercle 64 2 1983 111 118
49. S. Hosoglu, M.F. Geyik, and I. Balik Predictors of outcome in patients with tuberculous meningitis Int J Tuberc Lung Dis 6 2002 64 70
50. V. Quagliarello Adjunctive steroids for tuberculous meningitis: more evidence, more questions N Engl J Med 351 2004 1792 1794
51. G.E. Thwaites, D.B. Nguyen, and H.D. Nguyen Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults N Engl J Med 351 2004 1741 1751
52. A.K. Mohan, T.R. Cote, and J.A. Block Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor Clin Infect Dis 39 3 2004 300 302
53. Centers for Disease Control and Prevention Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003 MMWR Morb Mortal Wkly Rep 53 30 2004 683 686
54. J. Bieber, and A. Kavanaugh Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments Rheum Dis Clin North Am 30 2 2004 257 270
55. D.E. Snider, P.M. Layde, and M.W. Johnson Treatment of tuberculosis during pregnancy Am Rev Respir Dis 122 1980 65 79
56. M.T. Medchill Gillum. Diagnosis and management of tuberculosis during pregnancy Obstset Gynecol Surv 44 1989 81 89
57. P.T. Davidson Managing tuberculosis during pregnancy Lancet 346 1995 199 200
58. D.E. Snider, and K.E. Powell Should women taking antituberculosis drugs breast-feed? Arch Intern Med 144 1984 589 590
59. R.S. Malone, D.N. Fish, and D.M. Spiegel The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol Am J Respir Crit Care Med 159 1999 1580 1584
60. C.A. Peloquin Antituberculosis drugs: pharmacokinetics L. Heifets Drug susceptibility in the chemotherapy of mycobacterial infections 1991 CRC Press Boca Raton (FL) 59 88
61. I. Strauss, and F. Erhardt Ethambutol absorption, excretion and dosage in patients with renal tuberculosis Chemotherapy 15 1970 148 157
62. M. Ziersky, and E. Bek Side effects of drug regimens used in short course chemotherapy for pulmonary tuberculosis Tubercle 61 1980 41 49
63. D.J. Girling Adverse effects of antituberculosis drugs Drugs 23 1982 56 74
64. D. Yee, C. Valiquette, and M. Pelletier Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis Am J Respir Crit Care Med 167 2003 1472 1477
65. A.J. Mclean, and D.J. Morgan Clinical pharmacokinetics in patients with liver disease Clin Pharmacokinet 21 1991 42 69